Michael Roy

Michael Roy

South Australian Immunogenomics Cancer Institute

Faculty of Health and Medical Sciences


Dr Michael Roy was appointed in late 2024 as a Group Leader, and leads the Molecular & Proximity Discovery (MPD) Laboratory within the Resistance Prevention Program at South Australian immunoGENomics Cancer Institute (SAiGENCI). He brings extensive expertise in structure-guided discovery of inhibitors and modulators of Protein-Protein Interactions (PPIs), including Targeted Protein Degraders/PROTACs, and structurally deciphering the molecular mechanisms of cellular signalling.

Dr Roy completed his PhD in Medical Biology (Medicinal Chemistry) at the University of Melbourne/WEHI, before undertaking further postdoctoral training at the University of Dundee (Scotland) and Chemical Biology Division at WEHI (Australia). Prior to establishing his independent group at SAiGENCI, from 2020-2024 as Project Director, he co-led a significant academic/industry collaboration at WEHI to develop novel Protein Degraders to address targets of critical unmet need in cancer.

His research expertise in medicinal chemistry and structural biology targeting Protein-Protein Interactions (including BCL-2 family proteins, kinases/pseudokinases, ubiquitin E3 ligases and transcriptional regulators), in collaboration with leading experts internationally, has enabled pioneering structure-guided discovery of Inhibitors and Targeted Protein Degraders to address cancer vulnerabilities; including together with the Ciulli lab (Dundee) and Boehringer Ingelheim the development of ACBI1 and ACBI2, potent degraders of SMARCA2/4 helicase subunits of the SWI/SNF (BAF) chromatin remodelling complex, that is dysregulated in ~20% of human cancers.

His work has appeared in high-impact journals including Nature Chemical Biology, Science Signalling, ACS Chemical Biology, Nature Communications, JACS, Journal of Medicinal Chemistry. Over his research career, he has secured as Chief Investigator or Project Director more than $12 million in combined competitive grant, industry and philanthropic funding, and his research has directly resulted in 2 patents.

At SAiGENCI, Dr Roy’s group aims to advance cancer research through developing innovative therapeutic approaches (including small molecule Targeted Protein Degraders and Molecular Glues) to better combat resistance and address hitherto ‘undruggable’ nodes in cancer signalling.
The lab integrates a multisciplinary approach, incorporating medicinal chemistry, structural biology, biophysics, cell biology, proteomics, as well as computational design/machine learning; working with local and international collaborators, including the labs of Dr Fuyi Li and Dr Luke Isbel, SAiGENCI, and the Adelaide Drug Discovery Incubator (ADDI).

PhD, MPhil and Hons. degree projects are available in the team for motivated individuals with a passion to discover and build the medicines of tomorrow.

  • Education

    Date Institution name Country Title
    University of Melbourne Australia PhD
  • Journals

    Year Citation
    2024 Miller, M. S., Cowan, A. D., Brouwer, J. M., Smyth, S. T., Peng, L., Wardak, A. Z., . . . Czabotar, P. E. (2024). Sequence differences between BAX and BAK core domains manifest as differences in their interactions with lipids. FEBS Journal, 291(11), 2335-2353.
    DOI Scopus5 Europe PMC3
    2023 Roy, M. J., Surudoi, M. G., Kropp, A., Hou, J., Dai, W., Hardy, J. M., . . . Lucet, I. S. (2023). Structural mapping of PEAK pseudokinase interactions identifies 14-3-3 as a molecular switch for PEAK3 signaling. Nature Communications, 14(1), 3542.
    DOI Scopus7 Europe PMC8
    2022 Kofink, C., Trainor, N., Mair, B., Wöhrle, S., Wurm, M., Mischerikow, N., . . . Farnaby, W. (2022). A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nature Communications, 13(1), 5969.
    DOI Scopus123 Europe PMC77
    2022 Hou, J., Nguyen, E. V., Surudoi, M., Roy, M. J., Patel, O., Lucet, I. S., . . . Daly, R. J. (2022). Distinct PEAK3 interactors and outputs expand the signaling potential of the PEAK pseudokinase family. Science Signaling, 15(722), eabj3554.
    DOI Scopus9 Europe PMC6
    2021 Patel, O., Roy, M. J., Kropp, A., Hardy, J. M., Dai, W., & Lucet, I. S. (2021). Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1. Communications Biology, 4(1), 1105.
    DOI Scopus17 Europe PMC20
    2021 Liang, L. Y., Roy, M., Horne, C. R., Sandow, J. J., Surudoi, M., Dagley, L. F., . . . Lucet, I. S. (2021). The intracellular domains of the EphB6 and EphA10 receptor tyrosine pseudokinases function as dynamic signalling hubs. Biochemical Journal, 478(17), 3351-3371.
    DOI Scopus8 Europe PMC9
    2021 Mao, R., Xi, S., Shah, S., Roy, M. J., John, A., Lingford, J. P., . . . Goddard-Borger, E. D. (2021). Synthesis of C-Mannosylated Glycopeptides Enabled by Ni-Catalyzed Photoreductive Cross-Coupling Reactions. Journal of the American Chemical Society, 143(32), 12699-12707.
    DOI Scopus58 Europe PMC19
    2021 Roy, M. J., Vom, A., Okamoto, T., Smith, B. J., Birkinshaw, R. W., Yang, H., . . . Lessene, G. (2021). Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X<inf>L</inf>and BCL-2. Journal of Medicinal Chemistry, 64(9), 5447-5469.
    DOI Scopus9 Europe PMC4
    2020 Cowan, A. D., Smith, N. A., Sandow, J. J., Kapp, E. A., Rustam, Y. H., Murphy, J. M., . . . Czabotar, P. E. (2020). BAK core dimers bind lipids and can be bridged by them. Nature Structural and Molecular Biology, 27(11), 1024-1031.
    DOI Scopus52 Europe PMC41
    2020 Patel, O., Roy, M. J., Murphy, J. M., & Lucet, I. S. (2020). The PEAK family of pseudokinases, their role in cell signalling and cancer. FEBS Journal, 287(19), 4183-4197.
    DOI Scopus20 Europe PMC20
    2019 Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., . . . Ciulli, A. (2019). Publisher Correction: BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design (Nature Chemical Biology, (2019), 15, 7, (672-680), 10.1038/s41589-019-0294-6). Nature Chemical Biology, 15(8), 846.
    DOI Scopus10 Europe PMC5
    2019 Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., . . . Ciulli, A. (2019). BAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design. Nature Chemical Biology, 15(7), 672-680.
    DOI Scopus392 Europe PMC262
    2019 Roy, M. J., Winkler, S., Hughes, S. J., Whitworth, C., Galant, M., Farnaby, W., . . . Ciulli, A. (2019). SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. ACS Chemical Biology, 14(3), 361-368.
    DOI Scopus237 Europe PMC151
    2014 Roy, M. J., Vom, A., Czabotar, P. E., & Lessene, G. (2014). Cell death and the mitochondria: Therapeutic targeting of the BCL-2 family-driven pathway. British Journal of Pharmacology, 171(8), 1973-1987.
    DOI Scopus104 Europe PMC60
    2014 Brady, R. M., Vom, A., Roy, M. J., Toovey, N., Smith, B. J., Moss, R. M., . . . Lessene, G. (2014). De-novo designed library of benzoylureas as inhibitors of BCL-X <inf>L</inf>: Synthesis, structural and biochemical characterization. Journal of Medicinal Chemistry, 57(4), 1323-1343.
    DOI Scopus35 Europe PMC14
  • Book Chapters

    Year Citation
    2022 Patel, O., Surudoi, M., Dai, W., Hardy, J. M., Roy, M. J., & Lucet, I. S. (2022). Production and purification of the PEAK pseudokinases for structural and functional studies. In Methods in Enzymology (Vol. 667, pp. 1-35). Elsevier.
    DOI Scopus2 Europe PMC2
  • Preprint

    Year Citation
    2025 Liu, J., Roy, M., Isbel, L., & Li, F. (2025). Accurate PROTAC targeted degradation prediction with DegradeMaster.
    DOI
    2024 Ma, N., Bhattacharya, S., Muk, S., Jandova, Z., Schmalhorst, P. S., Ghosh, S., . . . Vaidehi, N. (2024). Frustration in the Protein-Protein interface Plays a Central Role in the Cooperativity of PROTAC Ternary Complexes.
    DOI
    2022 Lucet, I., Roy, M., Surudoi, M., Kropp, A., Hou, J., Dai, W., . . . Patel, O. (2022). When two’s a crowd - Structural mapping of PEAK pseudokinase interactions identifies 14 3 3 as a molecular switch for PEAK3/Crk signaling..
    DOI
    2021 Patel, O., Roy, M., Kropp, A., Dai, W., & Lucet, I. (2021). Structural basis for small molecule targeting of Doublecortin Like Kinase 1 DCLK1.
    DOI
    2018 Roy, M., Winkler, S., Hughes, S., Whitworth, C., Galant, M., Farnaby, W., . . . Ciulli, A. (2018). SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate.
    DOI

Connect With Me
External Profiles